Hyaluronidase Market Size & Share, by Source (Animal-Derived, Synthetic, Bio-Engineered); Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Cosmetology); Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5293
  • Published Date: Oct 05, 2023
  • Report Format: PDF, PPT

Companies Dominating the Hyaluronidase Landscape

top-features-companies
    • Sun Pharmaceutical Industries Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PrimaPharm Inc.
    • Valeant Pharmaceuticals
    • Halozyme Therapeutics
    • CooperSurgical Fertility Companies
    • Amphastar Pharmaceuticals Inc.
    •  Shreya Life Science
    • Bausch & Lomb Incorporated
    • Stemcell Technologies Inc.
    • Anika Therapeutics Inc.
    • Alteogen Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Alteogen Inc., a South Korean biotechnology company, announced that the recently completed Tergase clinical trial showed no cases of ADA, including neutralizing antibodies. Tergase is Alteogen's first proprietary product currently undergoing the pharmaceutical approval process by the Korean Ministry of Food and Drug Safety. Tergase is a stand-alone hyaluronidase product that can be used to treat various medical conditions, such as pain relief, edema treatment, and hyaluronic acid filler removal. In particular, compared to  animal-derived hyaluronidase products available on the market, this is a high quality, highly pure product  with very few impurities and has excellent few side effects. As a new recombinant human hyaluronidase, Alteogen hopes Tergase can be applied to new indications not currently  available for existing animal-derived products.
  • Halozyme Therapeutics, Inc. announced in June 2023  that argenx received approval from the U.S. Food and Drug Administration (FDA)  for VYVGART Hytrulo Injection with ENHANZE for subcutaneous use in the treatment of generalized myasthenia gravis in Adult patients positive for anti-acetylcholine receptor antibodies. 

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5293
  • Published Date: Oct 05, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of chronic disease and increasing support by the government on its research and development activities are some of the major factors anticipated to drive the growth of the cell culture consumables market.

The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2024 – 2036.

The major players in the market are Halozyme Therapeutics, CooperSurgical Fertility Companies, Amphastar Pharmaceuticals Inc., Shreya Life Science, Bausch & Lomb Incorporated, Stemcell Technologies Inc., Anika Therapeutics Inc., Alteogen Inc., and others.

The dermatology segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying